US Edition
News from MedCity News
If you want to know if MedCity News is credible or reliable, look no further. We rank MedCity News as High factuality. Find out more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Center
Center
byAd Fontes MediaCenter
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top MedCity News News
Stock MarketsNovartis is paying $120 million up front to secure rights to a Monte Rosa molecular glue degrader drug candidate as well as options for two others. The two companies began working together last year under an alliance focused on immune mediated-diseases.See the Story
Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs
100% Center coverage: 4 sources
Donald Trump · ChinaPutting aside the politics of this situation for the moment, here are some ways for commercial execs to navigate the current climate of volatility. The post How Pharma Marketers Can Prepare for Trump’s 200% Tariff Threat appeared first on MedCity News.See the Story
How Pharma Marketers Can Prepare for Trump’s 200% Tariff Threat
Coverage: 2 sources
